Interestingly, in vitro GM102 positively cooperates with pembrolizumab, an anti-PDCD1 (programmed cell death 1) antibody, which is useful in cancers with microsatellite instability (Lynch syndrome) with profiling lymphocytes towards TH1 cells (189, 198). Here, PDCD1 is linked to Lynch syndrome.